Biological therapies have fewer side effects than chemotherapy and can slow down tumor growth and block the spread of cancer. This article shares the global market outlook for biological therapies to treat cancer, including mAbs, cancer growth blockers, cancer vaccines, and more.
- Moderna’s Global mRNA Manufacturing Strategy: A Closer Look
- Beyond Moderna’s Regulatory Legacy: (Re)defining The mRNA Regulatory “Norm”
- Moderna’s Regulatory Journey: 3 Takeaways To Foster The mRNA Renaissance
- How Can Life Sciences Navigate M&A In 2023?
- Transitioning From Monoclonal Antibody To AAV Separation Science
- Navigating Claim Scope For Functionally Claimed Biological Compounds After Amgen v. Sanofi
- Best Practices For Cell Culture Media Fingerprinting
- Dispelling 4 Common Myths Of Data Quality Governance
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
Continued Performance Verification Of Analytical Procedures Using Chromatography Data Software
Continued performance verification of the analytical procedure lifecycle approach routinely examines performance data of a method over its lifecycle. This paper explores how to facilitate the continued procedure performance verification stage of the analytical procedure lifecycle approach.
The hMSC Standard In The Ivory Tower
We accepted the challenge and built a business to enable a system of high quality and scalable volumes (billions) of human mesenchymal stromal cells (hMSC), paired media systems, and Good Manufacturing Practice (GMP) bioprocess expertise. But, did it work?
What's Next For Our Evolving Workforce?
Learn about three industry survival methods that when applied can ensure generational workforces are blending cohesively: engagement, culture, and communication.
Dilution Of Multiple Buffer Concentrates With One Single-Use Flow Path
Discover a buffer management system suitable for application with capture, purification, and polishing chromatographic operations. The system can provide a continuous supply of multiple in-specification diluted buffers and more.
Screen Candidates And Select Better Leads For Developing Therapeutic Antibodies
We demonstrate a workflow that can be used to access broad plasma cell diversity and rapidly down-select lead candidates with functional profiling.
Design Agile Manufacturing With An Integrated Drug Product Ecosystem
Companies wanting to accelerate biomanufacturing operations and use resources efficiently need access to technologies and solutions that can safely and efficiently complete workflow from idea to injection.
Single-Use Technology For The Most Extreme Processes
Downstream processing for biologic drugs often requires the use of harsh chemicals that can damage SUT components. CPC designers identified a polymer to handle rough downstream chemicals.
Expanding The Cell And Gene Therapy Manufacturing Workflow
A university's training lab overcame operational challenges and create efficiencies in cell and gene therapy manufacturing to bolster its hands-on education for academics, industry researchers, and regulators.
Boost Performance With A Chromatography Resin Update
Workhouse resins developed in the 1980s are still used in many processes, but are you missing out on better productivity and performance? How do you know which resin to use in new projects?
A Compliant-Ready Workflow For Peptide-Based Multiple Attribute Method
Here, we demonstrate an end-to-end analytical workflow developed for the peptide-based multiple attribute method (MAM). This platform provides a compliant-ready environment for automated data acquisition, processing, and reporting of product quality attributes (PQAs) for a monoclonal antibody (mAb) standard.
- 03.30.23 -- The Potential Of RNA Exon Editing
- 03.29.23 -- Decide Your Product Strategy: Allogeneic vs. Autologous Cell Therapy
- 03.28.23 -- CGT's Highly Anticipated Regulatory Decisions
- 03.27.23 -- Unveil The Potential Of Your AAV Gene Therapy
- 03.23.23 -- Lessons From The Past: How Yesterday's History Can Improve Today's Treatment
CELL AND GENE LIVE
To achieve commercial success, a developed process must be scalable and suitable for a manufacturing environment. The scaling strategy depends on the type of cell therapy. Check out our latest Cell & Gene Live - now available On-Demand.Cell & Gene Live Archive
CELL AND GENE CONTENT COLLECTIONS
While both allogeneic and autologous therapies use similar technologies common to the growth of cells, the scale is different. In this e-book from Cell & Gene, we've curated insightful editorial that concentrates on the advancements of both allogeneic and autologous therapies and how to manufacture them at scale.More Content Collections